title: Diclofenac in the management of E. coli urinary tract infections.
abstract: E. coli is the main agent of uncomplicated urinary tract infections (UTIs) and accounts for more than 85% of recurrent cystitis and at least 35% of recurrent pyelonephritis. Despite the widespread availability of antibiotics, UTIs remain the most common bacterial infection in the human population. It is currently advised that the clinical administration of antibiotics against the pathogenic bacteria should be prohibitted due to the emergence of multidrug resistant (MDR) bacterial strains. Therefore, newer and more effective antimicrobials are in demand to treat such cases. One hundred and thirty six urine samples were collected from UTI patients. E. coli was isolated from 85 samples, out of which 33% were resistant to common antibiotics. The isolates were decreasingly resistant to ampicillin, tobramycin, augmentin, nalidixic acid, cefuroxime, nitrofurantoin, kanamycin, pipemidic acid, chloramphenicol, cefotaxime, cefamendol, ofloxacin, ceftizoxime, norfloxacin and amikacin. The anti-inflammatory drug diclofenac exhibited significant antibacterial activity against common bacterial strains both in vitro and in vivo. The present work was conducted to evaluate the in vitro inhibitory effect of this drug on the clinically isolated strains of E. coli in hospitals. All the isolates were sensitive to diclofenac, with MIC values ranging from 5-50 microg/mL. The MIC90 value of the drug was 25 microg/mL. Therefore, it may be suggested that diclofenac has the capacity to treat UTI caused by E. coli.
authors.affiliation: Division of Microbiology, Institute of Genetic Engineering, Kalyani University, Calcutta 700 128, India.
authors.forename: Kaushiki
authors.initials: K
authors.lastname: Mazumdar
authors.forename: Noton Kumar
authors.initials: NK
authors.lastname: Dutta
authors.forename: Sujata G
authors.initials: SG
authors.lastname: Dastidar
authors.forename: Noboru
authors.initials: N
authors.lastname: Motohashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Shirataki
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004008:Diclofenac / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000235:genetics; D004927:Escherichia coli Infections / Q000628:therapy* / Q000652:urine; D006801:Humans; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D016861:Cyclooxygenase Inhibitors; D004008:Diclofenac